title: Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer.
abstract: OBJECTIVE
  The efficacy of adjuvant chemotherapy in gastric cancer is controversial. We conducted a phase III, randomized, multicentric clinical trial with the goal of assessing the efficacy of the combination of mitomycin plus tegafur in prolonging the disease-free survival and overall survival of patients with resected stage III gastric cancer.
  
  
  METHODS
  Patients with resected stage III gastric adenocarcinoma were randomly assigned, using sealed envelopes, to receive either chemotherapy or no further treatment. Chemotherapy was started within 28 days after surgery according to the following schedule: mitomycin 20 mg/m(2) intravenously (bolus) at day 1 of chemotherapy; 30 days later, oral tegafur at 400 mg bid daily for 3 months. Disease-free survival and overall survival were estimated using the Kaplan-Meier analysis and the Cox proportional hazards model.
  
  
  RESULTS
  Between January 1988 and September 1994, 148 patients from 10 hospitals in Catalonia, Spain, were included in the study. The median follow-up period was 37 months. The tolerability of the treatment was excellent. The overall survival and disease-free survival were higher in the group of patients treated with chemotherapy (P =.04 for survival and P =.01 for disease-free survival in the log-rank test). The overall 5-year survival rate and the 5-year disease-free survival rate were, respectively, 56% and 51% in the treatment group and 36% and 31% in the control group.
  
  
  CONCLUSIONS
  Our positive results are consistent with the results of recent studies; which conclude that there is a potential benefit from adjuvant chemotherapy in resected gastric cancer.
authors.affiliation: Medical Oncology, Unit, Hospital Mútua de Terrassa-Universitat de Barcelona, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Cirera
authors.forename: A
authors.initials: A
authors.lastname: Balil
authors.forename: E
authors.initials: E
authors.lastname: Batiste-Alentorn
authors.forename: I
authors.initials: I
authors.lastname: Tusquets
authors.forename: T
authors.initials: T
authors.lastname: Cardona
authors.forename: A
authors.initials: A
authors.lastname: Arcusa
authors.forename: L
authors.initials: L
authors.lastname: Jolis
authors.forename: E
authors.initials: E
authors.lastname: Saigí
authors.forename: I
authors.initials: I
authors.lastname: Guasch
authors.forename: A
authors.initials: A
authors.lastname: Badia
authors.forename: M
authors.initials: M
authors.lastname: Boleda
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005641:Tegafur; D016685:Mitomycin